On the heels of positive study results at the 30th Transcatheter Cardiovascular Therapeutics meeting, Boston Scientific (NYSE:BSX) won FDA approval for its drug-eluting vascular stent system, Eluvia.
The device, which is designed for the treatment of peripheral artery disease, uses a drug-polymer combination to deliver paclitaxel over the course of a year.
Get the full story at our sister site, Drug Delivery Business News.
The post TCT 2018: Boston Scientific wins FDA nod for drug-eluting vascular stent appeared first on MassDevice.